This Penny Stock Has Triple-Digit Growth Potential

Last week's 10 top penny stocks soared as much as 218%, and we've found another one primed for triple-digit potential...

Last week's top performing penny stock, Orchids Paper Products Co. (NYSE: TIS), jumped over 218% after the company delivered a stellar earnings reports on Aug. 13.

penny stocksOrchids' triple-digit returns are a perfect example of the spectacular profit potential that select penny stocks can deliver. However, the key to locking in these kinds of returns is to buy a strong penny stock before it jumps dramatically.

After looking at last week's top performing penny stocks, we'll show you a penny stock that's on the verge of bringing you triple-digit returns...

Penny Stock Current Share Price Last Week's Gain
Orchids Paper Products Co. (NYSE: TIS) $2.60 218.83%
China Rapid Finance Ltd. (NYSE: XRF) $2.69 69.01%
Cel-Sci Corp. (NYSE: CVM) $1.21 42.17%
Regulus Therapeutics Inc. (Nasdaq: RGLS) $0.29 33.40%
Farmmi Inc. (Nasdaq: FAMI) $3.82 30.51%
Biolase Inc. (Nasdaq: BIOL) $1.85 29.93%
Navidea Biopharmaceuticals Inc. (NYSE: NAVB) $0.18 26.99%
Bellerophon Therapeutics Inc. (Nasdaq: BLPH) $0.92 25.56%
Inpixon (Nasdaq: INPX) $0.14 24.36%
JMU Ltd. (Nasdaq: JMU) $1.58 24.05%

While some of those returns look spectacular, we're not convinced these penny stocks will keep growing.

"Federal Rent Checks": Thanks to an obscure law, over 100 government agencies are required to pay rent. By following a simple investment strategy, you could receive checks of up to $1,795 every month. Read more...

Instead, we're looking for the next penny stocks with the potential to skyrocket.

And thanks to the Money Morning Stock VQScore™ system, we've found one.

This company is in the middle of an acquisition spree - one that's already paying off for the company's top line.

In fact, shares of this stock could soar 100% when Wall Street catches on...

[mmpazkzone name="in-story" network="9794" site="307044" id="137008" type="4"]

Top Penny Stocks to Watch in August, No. 1: PDL Biopharma Inc.

PDL Biopharma Inc. (Nasdaq: PDLI) is a holding company that manages the pharmaceutical patents generated by Facet Biotech, the company's research and development branch.

Over the last 12 months, PDL's stock has risen 40% - and for good reason. Since a majority of the company's original patent holdings expired in 2016, the company has undergone an aggressive restructuring effort to streamline profitability.

But that's just the beginning for this stock...

Shortly after several of PDL's holdings expired, the company established a majority ownership position in Noden Pharma, a pharmaceutical company that owns the popular blood pressure drug Tekturna.

This deal was PDL's first acquisition of a commercial asset that could directly generate income for the company - and it's been paying off.

In 2017, PDL grew its year-over-year revenue and beat earnings estimates for every quarter.

And PDL's current market valuation makes it an absolute bargain. PDL currently has an incredibly low price-to-book ratio of 0.5. As a result, if the company's share price rose to equal its book value, it would double - giving investors a 100% return.

At $2.53 a share, it's an absolute steal.

As PDL continues to stage a dramatic turnaround, this discrepancy will quickly be corrected -and penny stock investors should lock in this profit opportunity now.

Stocks like PDL, Lloyds, and Advantage are easy to identify thanks to the VQScore system.

However, not all winning stocks are this easy to find. That's why we follow the world's greatest stock picker.

His method has given readers the opportunity to lock in peak gains of 1,000% - repeatedly.

He hasn't just gotten lucky during the historic bull market run either...

This champion stock picker first gave his readers the chance at fortunes during a huge market crash - Black Monday, August 2011, when the United States' credit rating was downgraded for the first time in history.

And he's locked in astonishing gains on a nearly regular basis ever since...

Follow Money Morning on Facebook, Twitter, and LinkedIn.